The White House said Tuesday it is proposing a new rule to expand coverage of anti-obesity and diabetes medications made by companies such as Novo Nordisk (NVO) and Eli Lilly (LLY) for Americans with Medicare and Medicaid.
The new proposal would expand coverage that already includes diabetes and other illnesses, to include obesity, reducing out-of-pocket costs by as much as 95%, the White House said.
"This proposal would allow Americans and their doctors to determine the best path forward so they can lead healthier lives, without worrying about their ability to cover these drugs out-of-pocket, and ultimately reduce health care costs to our nation," the White House said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。